Slide 1: Ultrasonic Cardiac Output Monitor Broker Presentation
Ultrasonic Cardiac Broker Presentation Wednesday June 9, 2004 tput M
Slide 2: Agenda
Agenda: The Listing Milestones The USCOM Product Competition Growth Strategy Management Team Risks & Challenges
Slide 3: The Listing
The Listing: Listing Date: December 10, 2003 Cash Raised: $16,000,000 ASX Code: UCM Shares Offered: 8,000,000 Total Shares: 38,000,000 Listing price: $2.00 Trading range: $2.11 - $3.90
Slide 4: Milestones: December to March
11 December First of 6 validation studies presented 19 December CE Mark regulatory approval for Europe 19 January China regulatory approval 19 March First Sales to China 30 March University of NSW sale
Slide 5: Milestones: April to May sales and results
5 April 7 April 20 April April 22 May 10 May 24 North Asia sales — Japan, Korea, Taiwan S.E. Asia sales — Singapore, Malaysia, Philippines First Europe sales Quarterly results: $13.8m cash in hand South China sales — Macau follow-up sale 33 sales to date
Slide 6: The USCOM Cardiac Monitor
The USCOM Cardiac Monitor offering IMPROVED CARE ...at LOWER COST ..and with REDUCED RISK
Slide 7: Huge demand for a safe, more accurate solution
difficult or with variable accuracy. u Huge demand for a safe, more accurate and efficient’s lution. a
Slide 8: Survey of physicians and nurses worldwide
Survey of 700 physicians & nurses worldwide, conducted by General Electric Medica Systems. & GE Medicat $ ystems
Slide 9: Non-invasive, accurate, cost effective
u Non-Invasive u Accurate u Cost effective
Slide 10: USCOM is the most accurate clinical method of measuring haemodynamics
USCOM is the most accurate clinical method of measuring haemodynamics weaes and it is non-invasive.
Slide 11: Competition
“3 Competition METHOD seywodlecibe Noninvasive | Simple | Inexpensive | Portable Thermodilution (Tx) ++ Fick + + PiCCO (Mod Tx) ++ + + + + LidCo ++ + + + + Impedence (BioZ) + 44+ 44+ ++ + TOE Doppler 44 44+ ++ + + Doppler (USCOM) +++ +4+ 44+ +++ 4+4++ Comparison of desirable CO monitoring features
Slide 12: Catheterisation survival and hospitalisation costs
=~. Oo Without Catheter 2 o With Catheter Proportion Surviving °o fo) ~™ co o a 0 5 10 15 20 25 30 Follow-up Time (Days) Thirty-day survival curves for 2016 patients with and witnout catheterisation. SOURCE:Journal of the American Medical Association US$132,000 US$78,000 With Without Catheter Cathet
Slide 13: Applications
“Sein WO Applications u Anaesthetics u Paediatrics u Emergency Care u Intensive care u Renal medicine u Transplantation and pacemakers u Sleep medicine u General Practice u Nursing homes u Home monitoring u Sports Medicine
Slide 14: Validation
Validation: USCOM proven in 3 rigorous stages of validation 1. Laboratory based precision testing 2. Tested against Flow Probes in animals 3. Tested against Catheters — the “gold standard”
Slide 15: MECABIO Institute, France
MECABIO Institute, France Computer controlled haemodynamics model Exact agreement from —1.0 to 1.6 metres per second
Slide 16: Stage 2 - Flow Probes
OM STAGE 2- FLOW PROBES POW Hospital, Hong Kong Flow probes in dogs. Mean difference: 1.1% (n=335) Study presented at World Congress of Anaesthesiology Paris, May 2004 Florey Institute, Melbourne Flow probes in sheep Mean difference: Less than 1% (n=16)
Slide 17: Hospital validation studies
Royal Perth Hospital Hanover Uni. Hospital Sir Charles Gairdner, Perth
Slide 18: Validation: Other
Validation: oTHER Training protocol: Fremantle Emergency Dept Ventilation: Chennai Hospital Electrophysiology: Hong Kong University Paediatrics: Green Lane, New Zealand
Slide 19: Business, Science, Operations
Business Science Operations Gary Davey (Chief Executive) Rob Phillips (Chairman) Paul Butler (General Manager & Operations)
Slide 20: Advisory Board
Advisory Board: Mr Rob Phillips F.1.8., D.M.U, AMS Dr Fred Berry MBBS, FANZCA Professor Stephane Carlier Mb, Ph.D. Professor Colin Sullivan MD PhD FRACP Dr Greg Clark Ph.D Professor Malcolm West MBBS, PhD, FRACP Professor C.P. Lau MBBS, MD Chairman of USCOM Leading Anaesthetist Cardiologist, Biomedi
Slide 21: Growth Strategy
Growth Strategy: Global network of marketing partners — mostly variable cost Initial focus on hospital market — cu, ER & Anaesthetics Initial focus on Asia & Europe markets US market entry mid 2005 Continue evolution of USCOM #1A Roll-out product pipeline Grow LP. portfolio Build world class managem
Slide 22: It takes time to change medical practice
It takes time to change medical practice Capital budgets in hospitals very tight Australian hospitals especially slow to adopt new tech US Market entry will be challenging No guarantee our patents won’t be attacked in the future
Slide 23: A unique product with a global market
A unique product with a global market Adequately resourced for identifiable needs Highly focused on products, target customers & markets Operating on low fixed costs Meeting its milestones Building a quality team for the long term